Predicting Stroke Risk in ICAD With Novel MRI

Launched by NORTHWESTERN UNIVERSITY · Aug 22, 2022

Keywords

ClinConnect Summary

This clinical trial is studying how a new type of MRI can help predict the risk of stroke in patients with intracranial atherosclerosis (ICAD), a condition where blood vessels in the brain become narrowed. The goal is to better understand different brain lesions and the effectiveness of various treatment options. By analyzing patients’ MRI results and their treatment outcomes, researchers hope to find which treatments work best in preventing strokes and improving patient care.

To participate in this trial, individuals must be between 18 and 85 years old and have been diagnosed with intracranial atherosclerosis. They should be experiencing symptoms related to this condition, which could include transient ischemic attacks (TIAs) or strokes. Participants will undergo MRI scans and may receive different treatment options based on their specific condition. It's important to note that certain individuals, such as those with severe medical conditions or who are unable to tolerate MRI scans, may not be eligible for the study. Overall, this trial aims to enhance how doctors predict and manage stroke risk in patients with ICAD, ultimately improving patient outcomes.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Age greater than 18 - 85 years
• • All symptomatic patients referred to the Stroke Neurology, Cerebrovascular Surgery, or Interventional Neuroradiology inpatient/outpatient clinical services at Northwestern University or the University of Chicago with diagnosis of intracranial atherosclerosis.
• • CTA/MRA/DSA imaging findings confirm the presence of moderate to severe stenosis \>50% of ≥ 1 segment of the supra-clinoid ICA, A1-A2 ACA, M1-M2 MCA, distal vertebral-basilar artery, P1-P2 PCA and complete cervical or intracranial carotid occlusions utilizing the SAMMPRIS stenosis criteria (3) Symptomatic patients defined as an association between the intracranial stenosis and perfusion/thromboembolic ischemia related symptoms of the corresponding vascular territory, based on either neurological exam (TIAs/stroke) and/or acute/subacute infarcts documented on MR-DWI within 7 days of presentation.
• Exclusion Criteria:
• • Standard contraindications to MRI: claustrophobia, metallic implants, pacemaker, compromised kidney function (GFR \< 40 ml/min), history of reaction to MRI contrast agent, history of allergic reactions to ferumoxytol or other IV iron products,
• • elderly patients \> 85 years
• • multiple or serious medical conditions, or history of multiple drug allergies Other confounders of neuro-functional exams, i.e. Alzheimer's Disease or dementia.
• • Severe \>70% cervical carotid or vertebral artery proximal stenosis, or tandem intracranial stenosis
• • VULNERABLE POPULATIONS
• • N/A